Piercarlo Ballo1, Daniela Balzi2, Alessandro Barchielli3, Lucia Turco4, Flavia Franconi5, Alfredo Zuppiroli6. 1. Cardiology Unit - S. Maria Annunziata Hospital, Florence, Italy. pcballo@tin.it. 2. Epidemiology Unit - Local Health Unit, Florence, Italy. 3. Institute for Oncological Studies and Prevention, Florence, Italy. 4. Sanitary Direction - Local Health Unit, Pistoia, Italy. 5. Department of Biomedical Sciences, University of Sassari, Sassari, Italy. 6. Regional Health Agency of Tuscany, Florence, Italy.
Abstract
PURPOSE: The existence of gender differences in the management of statin therapy among patients with chronic heart failure (HF) is still poorly investigated. We aimed at exploring the effect of gender on statin prescription rates and adequacy of dosing and on the association between statin therapy and all-cause 1-year mortality, after HF hospitalization in a community setting. METHODS: Statin prescription rates, adequacy of dosing (estimated as a PDD/DDD ratio >0.80), and 1-year mortality were retrospectively assessed in 2088 consecutive patients discharged from 5 local community hospitals with a definite diagnosis of HF after a mean length of stay of 7.6 days. The effect of gender was explored using multivariable logistic and Cox analyses adjusting to confounders. RESULTS: Women showed a lower statin prescription rate (25.7 vs 35.3%, P < 0.0001) and a lower prevalence of adequate statin dose (32.6 vs 42.3%, P < 0.0001) than men. Female gender was independently associated with a 24% lower probability of statin prescription and a 48% higher probability of inadequate statin dose. Statin prescription and adequacy of dosing were associated with 35 and 44% decreases in the risk of 1-year mortality, respectively, irrespective of gender. A nested case/control analysis confirmed that adequate statin dose was associated with 48% lower 1-year mortality, again without interaction with gender. CONCLUSIONS: In patients with chronic HF, female gender is independently associated with lower statin prescription rates and higher probability of inadequate dose. Statin therapy in these subjects is associated with improved 1-year survival in both men and women. This prognostic benefit is not affected by gender.
PURPOSE: The existence of gender differences in the management of statin therapy among patients with chronic heart failure (HF) is still poorly investigated. We aimed at exploring the effect of gender on statin prescription rates and adequacy of dosing and on the association between statin therapy and all-cause 1-year mortality, after HF hospitalization in a community setting. METHODS: Statin prescription rates, adequacy of dosing (estimated as a PDD/DDD ratio >0.80), and 1-year mortality were retrospectively assessed in 2088 consecutive patients discharged from 5 local community hospitals with a definite diagnosis of HF after a mean length of stay of 7.6 days. The effect of gender was explored using multivariable logistic and Cox analyses adjusting to confounders. RESULTS:Women showed a lower statin prescription rate (25.7 vs 35.3%, P < 0.0001) and a lower prevalence of adequate statin dose (32.6 vs 42.3%, P < 0.0001) than men. Female gender was independently associated with a 24% lower probability of statin prescription and a 48% higher probability of inadequate statin dose. Statin prescription and adequacy of dosing were associated with 35 and 44% decreases in the risk of 1-year mortality, respectively, irrespective of gender. A nested case/control analysis confirmed that adequate statin dose was associated with 48% lower 1-year mortality, again without interaction with gender. CONCLUSIONS: In patients with chronic HF, female gender is independently associated with lower statin prescription rates and higher probability of inadequate dose. Statin therapy in these subjects is associated with improved 1-year survival in both men and women. This prognostic benefit is not affected by gender.
Authors: Bruce K Birmingham; Sarah R Bujac; Robert Elsby; Connie T Azumaya; Cheryl Wei; Yusong Chen; Rogelio Mosqueda-Garcia; Helen J Ambrose Journal: Eur J Clin Pharmacol Date: 2015-02-12 Impact factor: 2.953
Authors: J M H Galema-Boers; M J Lenzen; R T van Domburg; J Roeters van Lennep; G G van Bruchem-van de Scheur; E J Sijbrands; J G Langendonk Journal: Eur J Clin Pharmacol Date: 2014-01-22 Impact factor: 2.953
Authors: Caroline Daly; Felicity Clemens; Jose L Lopez Sendon; Luigi Tavazzi; Eric Boersma; Nicholas Danchin; Francois Delahaye; Anselm Gitt; Desmond Julian; David Mulcahy; Witold Ruzyllo; Kristian Thygesen; Freek Verheugt; Kim M Fox Journal: Circulation Date: 2006-01-31 Impact factor: 29.690
Authors: Praful Schroff; Christopher M Gamboa; Raegan W Durant; Asikhame Oikeh; Joshua S Richman; Monika M Safford Journal: J Am Heart Assoc Date: 2017-08-28 Impact factor: 5.501
Authors: Cristina Soriano-Maldonado; Adriana Lopez-Pineda; Domingo Orozco-Beltran; Jose A Quesada; Jose L Alfonso-Sanchez; Vicente Pallarés-Carratalá; Jorge Navarro-Perez; Vicente F Gil-Guillen; Jose M Martin-Moreno; Concepción Carratala-Munuera Journal: Int J Environ Res Public Health Date: 2021-11-25 Impact factor: 3.390
Authors: Christopher J Rush; Ross T Campbell; Pardeep S Jhund; Mark C Petrie; John J V McMurray Journal: Eur Heart J Date: 2018-10-01 Impact factor: 29.983
Authors: Fahri Bayram; Alper Sonmez; Cem Haymana; Tevfik Sabuncu; Oguzhan Sitki Dizdar; Eren Gurkan; Ayse Kargili Carlioglu; Kemal Agbaht; Didem Ozdemir; Ibrahim Demirci; Cem Barcin; Serpil Salman; Tamer Tetiker; Mustafa Kemal Balci; Nur Kebapci; Canan Ersoy; Volkan Yumuk; Peter P Toth; Ilhan Satman Journal: Lipids Health Dis Date: 2020-11-11 Impact factor: 3.876